2024
Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR-T therapies in autoimmunity
Bodansky A, Yu D, Rallistan A, Kalaycioglu M, Boonyaratanakornkit J, Green D, Gauthier J, Turtle C, Zorn K, O'Donovan B, Mandel-Brehm C, Asaki J, Kortbawi H, Kung A, Rackaityte E, Wang C, Saxena A, de Dios K, Masi G, Nowak R, O'Connor K, Li H, Diaz V, Saloner R, Casaletto K, Gontrum E, Chan B, Kramer J, Wilson M, Utz P, Hill J, Jackson S, Anderson M, DeRisi J. Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR-T therapies in autoimmunity. Journal Of Clinical Investigation 2024, 134: e180012. PMID: 38753445, PMCID: PMC11213466, DOI: 10.1172/jci180012.Peer-Reviewed Original ResearchB-cell maturation antigenImmunomodulatory therapyPlasma cell-targeted therapyCAR-T therapyCell-targeted therapyAutoantibody mediated diseasesCAR-TAnti-CD19Maturation antigenAutoantibody profileAutoreactive antibodiesTargeted therapyPlasma cellsAutoimmune diseasesAutoantibody repertoireTherapyMediated diseasesAutoantibodiesTherapeutic interventionsProteome-wideDisease statesDiseaseImmunological fingerprintPhIP-SeqMinimal effect
2022
Novel pathophysiological insights in autoimmune myasthenia gravis
Masi G, O’Connor K. Novel pathophysiological insights in autoimmune myasthenia gravis. Current Opinion In Neurology 2022, 35: 586-596. PMID: 35942663, PMCID: PMC9458626, DOI: 10.1097/wco.0000000000001088.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAutoimmune myasthenia gravisMyasthenia gravisMG patientsClinical responseMuscle-specific tyrosine kinaseSpecific therapeutic strategiesNovel pathophysiological insightsMG pathologyMG subtypesAutoantibody repertoireTreatment optionsCancer immunotherapyPredictive biomarkersSuch therapyImmunological heterogeneityPathophysiological insightsMG phenotypeTherapeutic strategiesClinical observationsTherapeutic outcomesAcetylcholine receptorsDisease subtypesTherapeutic perspectivesSubtypesDevelopment of assays